EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system

L A Morland, B Chargin, B Rothbaum, J L Maples-Keller, T Wachsman, S B Norman, S N Adams, D Perivoliotis, A Alam, C S Stauffer, A C Angkaw, V Marquez und 3 weitere

Contemporary Clinical Trials Communications · 2026-12 · 54 · 101705

DOI: 10.1016/j.conctc.2026.101705 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Contemporary Clinical Trials Communications, 2026-12. Verfasst von L A Morland und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterans Affairs National Center for PTSD Women's Health Sciences Division, 150 South Huntington Street, Boston, MA, 02130, USA. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Posttraumatic stress disorder (PTSD) remains prevalent and disabling, especially among veterans, with a substantial proportion failing to achieve remission following first-line evidence-based trauma-focused psychotherapies. 3,4-Methylenedioxymethamphetamine (MDMA) is hypothesized to enhance psychotherapy outcomes through effects on fear extinction, cognitive flexibility, and emotional engagement, and is being studied as a promising augmentation strategy for PTSD psychotherapy. There is limited research combining MDMA with evidence-based PTSD treatment. MDMA-assisted psychotherapy trials to date have also been limited by lack of an active comparator and functional unmasking. We describe the methodology of an ongoing randomized, double-masked, pilot trial evaluating massed prolonged exposure (PE) therapy enhanced with MDMA for PTSD (aMETEMP), adapted for a U.S. Veterans Affairs outpatient setting. Up to 20 veterans with PTSD in the VA will receive a 6-8hr in-person MDMA dosing session (randomized dose 35 mg - 125 mg) integrated with a 3-week massed exposure protocol. The remaining visits are virtual and include PE sessions and sessions to prepare for and process the MDMA session (28-30hrs total over 11 visits), with the use of telehealth intended to improve access and ease patient burden. After treating the first 4 participants, who were fully informed of the trial design, we switched to using an incomplete disclosure strategy (not disclosing the number of treatment arms or specific possible doses) to further improve masking. Primary outcomes include PTSD severity using the Clinician-Administered PTSD Scale for DSM-5, safety, feasibility, and masking success. Findings are intended to provide preliminary descriptive information regarding feasibility, safety/tolerability, masking integrity, and symptom-change signals for aMETEMP with incomplete disclosure in a large outpatient healthcare system. ClinicalTrialsgov Identifier: NCT06117306.

Schlagwörter

Stichwörter der Autor:innen

MDMAMassed prolonged exposurePTSDVeteran

Autor:innen und Institutionen

  • Department of Veterans Affairs National Center for PTSD Women's Health Sciences Division, 150 South Huntington Street, Boston, MA, 02130, USA.
  • Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
  • Department of Psychiatry, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
  • Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive, Atlanta, GA, 30329, USA.
  • San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, 6363 Alvarado Court, San Diego, CA, 92120, USA.
  • National Center for PTSD Executive Division, VA Medical Center, 215 N. Main Street, White River Junction, VT, 05009, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Morland, L. A., Chargin, B., Rothbaum, B., Maples-Keller, J. L., Wachsman, T., Norman, S. B., Adams, S. N., Perivoliotis, D., Alam, A., Stauffer, C. S., Angkaw, A. C., Marquez, V., Woolley, J., Kopelman, J. M., & Schnurr, P. P. (2026). Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system. Contemporary Clinical Trials Communications, 54, 101705. https://doi.org/10.1016/j.conctc.2026.101705

Vancouver

Morland LA, Chargin B, Rothbaum B, Maples-Keller JL, Wachsman T, Norman SB, et al. Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system. Contemporary Clinical Trials Communications. 2026;54:101705. doi:10.1016/j.conctc.2026.101705

BibTeX
@article{Morland2026,
  author = {Morland, L A and Chargin, B and Rothbaum, B and Maples-Keller, J L and Wachsman, T and Norman, S B and Adams, S N and Perivoliotis, D and Alam, A and Stauffer, C S and Angkaw, A C and Marquez, V and Woolley, J and Kopelman, J M and Schnurr, P P},
  title = {Adapted Massed Exposure Therapy Enhanced with MDMA for PTSD (aMETEMP): A randomized, double-masked protocol adapted for Veterans Affairs healthcare system},
  journal = {Contemporary Clinical Trials Communications},
  year = {2026},
  volume = {54},
  pages = {101705},
  doi = {10.1016/j.conctc.2026.101705}
}
Kostenlos starten →